Vol. 61 No. 8 (2022): Acta Oncologica

Articles

• Second primary cancer following primary oral squamous cell carcinoma: a population-based, retrospective study

  Lasse Østrup Petersen, Jakob Schmidt Jensen, Kathrine Kronberg Jakobsen, Christian Grønhøj, Irene Wessel, Christian von Buchwald

  916-921

  Published: 2022-08-03

  • PDF
  • supplementary material

• Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study

  Anne Hansen Ree, Gunhild M. Mælandsmo, Kjersti Flatmark, Hege G. Russnes, Mónica Gómez Castañeda, Eline Aas

  955-962

  Published: 2022-08-03

  • PDF

• Bone versus soft-tissue setup in proton therapy for patients with oesophageal cancer

  Muhammad Shamshad, Ditte Sloth Møller, Hanna Rahbek Mortensen, Mai Lykkegaard Ehmsen, Maria Fuglsang Jensen, Lone Hoffmann

  994-1003

  Published: 2022-08-03

  • PDF

• Nonepithelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)

  Cristina Daviu, Jan Blaakaer, Ane Gerda Z. Eriksson, Jørn Herrstedt, M. P. Vandborg, Anne Mette Odgaard Rasmussen, Katrine Fuglsang

  939-945

  Published: 2022-08-03

  • PDF

• Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy

  Pierre Loap, Ester Orlandi, Ludovic De Marzi, Viviana Vitolo, Amelia Barcellini, Alberto Iannalfi, Rémi Dendale, Youlia Kirova, Alfredo Mirandola

  979-986

  Published: 2022-08-03

  • PDF

• Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort study

  Noortje Verschoor, Wilma D. Heemsbergen, Joost L. Boormans, Martine Franckena

  1019-1025

  Published: 2022-08-03

  • PDF

• Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study

  Ruzan Udumyan, Edoardo Botteri, Tomas Jerlstrom, Scott Montgomery, Karin E. Smedby, Katja Fall

  922-930

  Published: 2022-08-03

  • PDF
  • supplementary material

• 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial

  Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen

  963-971

  Published: 2022-08-03

  • PDF

• Dosimetric effects of respiratory motion during stereotactic body radiation therapy of lung tumors

  Sebastian Sarudis, Anna Karlsson, Jan Nyman, Anna Bäck

  1004-1011

  Published: 2022-08-03

  • PDF

• Cancer in the Faroe Islands from 1960-2019 – incidence, mortality, and comparisons with the other Nordic countries

  Marnar F. Kristiansen, Ronja M. Mikkelsen, Tordis Kristiansdóttir, Páll Rasmussen, Guðrið Andórsdóttir, Sæunn Ó. Hansen, Kári R. Nielsen, Bjarni á Steig, Marin Strøm, Maria Skaalum Petersen

  907-915

  Published: 2022-08-03

  • PDF
  • Supplementary

• A nationwide study on characteristics and outcome of cancer patients with sepsis requiring intensive care

  Edda Vesteinsdottir, Martin Ingi Sigurdsson, Magnus Gottfredsson, Asbjorn Blondal, Sigurbergur Karason

  946-954 |

  Published: 2022-08-03

  • PDF
  • supplementary material

• Timing of radiotherapy and chemotherapy start for patients treated with definitive concurrent chemoradiation for head and neck cancer

  Cole R. Steber, Gregory B. Russell, Marie C. Rush, Rachel F. Shenker, Bart. A. Frizzell, Kathryn M. Greven, Ryan T. Hughes

  987-993

  Published: 2022-08-03

  • PDF

• The incidence of brainstem toxicity following high-dose conformal proton therapy for adult skull-base malignancies

  Adam L. Holtzman, Michael S. Rutenberg, Alexandra N. De Leo, Dinesh Rao, Jeet Patel, Christopher G. Morris, Daniel J. Indelicato, William M. Mendenhall

  1026-1031

  Published: 2022-08-03

  • PDF

• Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis

  Anne Katrine Duun-Henriksen, Christian Dehlendorff, Martin Andreas Røder, Charlotte Skriver, Anton Pottegård, Søren Friis, Klaus Brasso, Signe Benzon Larsen

  931-938

  Published: 2022-08-03

  • PDF

• Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study

  Sebastian Søby, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Kinga Nowicka-Matus, Trine Tramm, Jesper Grau Eriksen

  972-978

  Published: 2022-08-03

  • PDF

• A practical method to improve the performance of knowledge-based VMAT planning for endometrial and cervical cancer

  Zheng Kang, Lirong Fu, Liwan Shi, Yimin Li

  1012-1018

  Published: 2022-08-03

  • PDF